Toni WeinschenkChief Technology Officer at Immatics Biotechnologies
Toni Weinschenk co-founded Immatics Biotechnologies GmbH in 2000.
He is Chief Technology Officer at Immatics Biotechnologies GmbH and at Immatics US Inc., where he oversees Immatics’ target discovery, target validation and companion diagnostics activities.
Over the past two decades, Toni Weinschenk has been active in the field of cancer immunology.
He is the inventor of Immatics’ proprietary XPRESIDENT® technology platform, which is enabling the discovery and validation of the most comprehensive array of cancer targets derived from both, cell surface and intracellular antigens. Toni Weinschenk has earned the reputation as leading expert in ultra-sensitive, quantitative and high-throughput mass spectrometry of HLA ligands, a technology that is integral to XPRESIDENT®. Targets identified by XPRESIDENT® have proven to be important assets in several licensing deals with partners from the pharma industry and academia.
Toni Weinschenk is an inventor on many patents and co-authored publications in the cancer immunology field in prestigious peer-reviewed journals including Nature, Nature Medicine, Nature Immunology, Nature Communications, Immunological Reviews, Cell Report and Proteomics.
Toni Weinschenk studied biochemistry at the University of Tuebingen (Hans-Georg Rammensee lab), Germany and at the Max-Planck-Institute, Munich, Germany.